Literature DB >> 6814270

Monoclonal antibodies against human chorionic gonadotropin (hCG): I. production, specificity, and intramolecular binding sites.

R Kofler, P Berger, G Wick.   

Abstract

Thirty-nine monoclonal antibody (MCA) producing hybridoma cell lines derived from fusions of mouse myeloma cells with spleen cells from mice immunized with human chorionic gonadotropin (hCG) have been established. Their products have been tested in radioimmunoassays using 125I-labeled hCG, luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), the alpha (alpha) and beta (beta) subunits of hCG and LH, and the C-terminal peptide 109-145 (CTP) of CG. All MCA were, in addition, tested in indirect immunofluorescence (IIF) on paraffin sections of human pituitary glands. According to the intramolecular localization of the determinants recognized, three main groups of MCA can be distinguished: 1) MCA directed against epitopes on the alpha-chain(alpha-MCA), 2) MCA directed against beta-chain determinants(beta-MCA), and 3) MCA reacting with a conformational determinant only present on the native hormone and not on either subunit (conformational-MCA). All alpha-MCA cross-react with human LH, FSH, and TSH. The beta-MCA do not react with FSH or TSH, but do react to a varying degree with LH. The conformational-MCA show no binding of labeled FSH or TSH and very little or no cross-reactivity with LH. (Am J Reprod Immunol. 1982; 2:212-216.)

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6814270     DOI: 10.1111/j.1600-0897.1982.tb00168.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 0271-7352            Impact factor:   3.886


  5 in total

1.  Enhanced urothelial expression of human chorionic gonadotropin beta (hCGβ) in bladder pain syndrome/interstitial cystitis (BPS/IC).

Authors:  Thilo Schwalenberg; Jens-Uwe Stolzenburg; Thi Phuc Ho; Tobias Mallock; Siegurd Hartenstein; Henry Alexander; Gerolf Zimmermann; Rudolf Hohenfellner; Stefan Denzinger; Maximilian Burger; Lars-Christian Horn; Jochen Neuhaus
Journal:  World J Urol       Date:  2011-08-30       Impact factor: 4.226

2.  Enhancement in antigen binding by a combination of synergy and antibody capture.

Authors:  T Klonisch; G Panayotou; P Edwards; A M Jackson; P Berger; P J Delves; T Lund; I M Roitt
Journal:  Immunology       Date:  1996-10       Impact factor: 7.397

3.  Vaccination with the repeat β-hCG C-terminal peptide carried by heat shock protein-65 (HSP65) for inducing antitumor effects.

Authors:  Jie Yang; Yankai Zhang; Huaqian Wang; Zhenqiu Gao; Zeyu Wang; Bin Liu; Xiuhua Zhang; Mingzhu Du; Xiao Huang; Maolei Xu; Jie Wu; Taiming Li; Jingjing Liu; Rongyue Cao
Journal:  Tumour Biol       Date:  2012-07-29

4.  Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine.

Authors:  N Kvirkvelia; N Chikadze; J Makinde; J D McBride; N Porakishvili; F A Hills; P M Martensen; J Justesen; P J Delves; T Lund; I M Roitt
Journal:  Clin Exp Immunol       Date:  2018-05-07       Impact factor: 4.330

5.  Candidate epitopes for measurement of hCG and related molecules: the second ISOBM TD-7 workshop.

Authors:  P Berger; E Paus; P M Hemken; C Sturgeon; W W Stewart; J P Skinner; L C Harwick; S C Saldana; C S Ramsay; K R Rupprecht; K H Olsen; J-M Bidart; U-H Stenman
Journal:  Tumour Biol       Date:  2013-09-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.